We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




HORIBA Acquires MedTest Dx and Pointe Scientific to Expand Laboratory Chemistry Offerings

By LabMedica International staff writers
Posted on 03 Feb 2021
Print article
Illustration
Illustration
HORIBA, Ltd. (Kyoto, Japan) has acquired MedTest Holdings, Inc. (Canton, MI, USA), composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.).

HORIBA Medical provides an extensive and complete line of hematology and clinical chemistry analyzers (including reagents) for use in In-vitro Diagnostics. MedTest Dx manufactures chemistry reagents and offers diagnostic solutions for decentralized clinical testing, providing a combination of screening instruments and reagent manufacturing in medical technologies, with a wide portfolio of products for IVD testing laboratories. The acquisition will combine the complimentary innovative technology offerings of HORIBA Medical with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.

"Our long term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative Chemistry and Immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest," said Mr. Atsushi Horiba, Chairman & Group CEO of HORIBA, Ltd.

"This acquisition provides HORIBA Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's high quality Chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen2 brand and current distribution channels," said HORIBA Medical segment leader Dr. Jai Hakhu, Chairman and CEO of HORIBA Instruments Incorporated and President of HORIBA ABX SAS in France.

Related Links:
HORIBA, Ltd.
MedTest Holdings, Inc.


New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Cortisol/Cortisone Saliva Controls
MassCheck Chromsystems Saliva Controls
New
Urine Strips
11 Parameter Urine Strips

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.